TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Telix Pharmaceuticals Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026
$10.74+0.05 (+0.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Telix Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $3.64B | $166.30M |
| Enterprise Value | $3.90B | $88.19M |
| PS Ratio | 4.53 | 3.65 |
Enterprise value
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 4.86 | 2.51 |
| EV / EBITDA | 76.25 | 14.65 |
| EV / EBIT | 131.08 | 19.00 |
Income (trailing twelve months)
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $803.79M | $58.34M |
| Gross Profit | $426.44M | $105.94M |
| Operating Income | $29.78M | -$21.40M |
| Pretax Income | -$5.27M | -$14.34M |
| Net Income | -$7.13M | -$22.46M |
| EBITDA | $51.19M | -$16.91M |
| EPS (Diluted) | -$0.02 | -$0.83 |
Margins
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 53.1% | 52.9% |
| Operating Margin | 3.70% | -44.0% |
| Pretax Margin | -0.66% | -13.3% |
| Profit Margin | -0.89% | -40.2% |
| EBITDA Margin | 6.37% | -30.2% |
| FCF Margin | -5.35% | -9.27% |
Returns
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -0.52% | -40.9% |
| Return on Capital Employed (ROCE) | 2.66% | -38.1% |
Growth
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 55.6% | 5.96% |
| Net Income Growth (YoY) | -121.2% | -35.2% |
| EPS Growth (YoY) | -121.6% | -26.2% |
| FCF Growth (YoY) | -334.0% | 2.34% |
Balance sheet
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $251.91M | $61.43M |
| Total Debt | $516.39M | $118.52M |
| Net Cash (Debt) | -$264.48M | $15.35M |
| Net Cash Per Share | -$0.78 | $0.66 |
| Working Capital | $245.68M | $76.81M |
Financial position
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.01 | 3.34 |
| Quick Ratio | 1.71 | 2.44 |
| Debt / EBITDA | 10.09 | 3.44 |
| Net Debt / EBITDA | 5.17 | 2.36 |
| Interest Coverage | 0.73 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$17.29M | -$12.35M |
| Capital Expenditures | -$25.69M | -$1.08M |
| Free Cash Flow | -$42.99M | -$20.22M |
| FCF Per Share | -$0.13 | -$0.42 |
Efficiency
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.59 | 0.39 |
| Inventory Turnover | 9.67 | 2.70 |
| Revenue Per Employee | $717.67K | $404.87K |
| Profits Per Employee | -$6.36K | -$703.34K |
| Employee Count | 1,120 | 74 |
Dividends and yields
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -0.20% | -23.3% |
| FCF Yield | -1.18% | -8.72% |
Shares
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 338,777,000 | 58,127,000 |
| Shares Change (YoY) | -2.12% | 10.9% |
| Float | 310,808,000 | 49,136,700 |
| Shares Held by Insiders | 8.26% | 11.6% |
| Shares Held by Institutions | 0.94% | 59.4% |
Taxes
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $1.86M | $79.87K |
Scores
| Measure | Telix Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 3.26 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Telix Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.